The $136.8 billion revenue drug wholesaler and medical supplier managed 5.3% sales growth in 2018 despite an increasingly challenging environment largely due to greater sales of high-price drugs used in oncology, among other medical specialties. The bulk of Cardinal’s revenue comes from the medications it distributes to pharmacies and is impacted by fluctuations in drug prices. The declining price of generics has weighed on the company’s bottom line in recent years and the heightened scrutiny of drug pricing has created uncertainty for Cardinal and its two bigger rivals, McKesson and AmerisourceBergen. The industry is also under continued pressure—and faces a growing number of lawsuits—over its alleged role in the nation’s opioid epidemic.
Looking for leads, investment insights, or competitive intelligence?
News about Cardinal Health
Attorney General Jeff Sessions announced a "statement of intent" to prop up suits against opioid makers and distributors.
Sparking a selloff in the shares of a host of health care-related companies.
Amazon is reportedly talking to drug firms.
The special Sino Saturday edition of CEO Daily.
Corporate governance matters, too.